FindTrial
Sign In

The mechanism for Parabacteroides distasonis improving hepatic fibrosis

The mechanism for Parabacteroides distasonis improving hepatic fibrosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200067222
Enrollment
Unknown
Registered
2022-12-29
Start date
2022-12-31
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic fibrosis

Interventions

Left and right liver fibrosis and cirrhosis group:N/A
Healthy control group:N/A

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years. 2. Patients diagnosed with hepatic fibrosis. 3. Patients residing in Chengdu urban area. 4. Patients who gave informed consent to this study and voluntarily participate.

Exclusion criteria

Exclusion criteria: 1.Combined with other metabolic diseases and infectious diseases. 2. Use of antibiotics, probiotics, prebiotics and other drugs known to affect the gut microbiota within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Diversity of gut microbiota;Biochemical index;Metabolomics analysis for serum;Metabolomics analysis for feces;—

Countries

China

Contacts

Public ContactLi Fei

West China Hospital of Sichuan University

feili@wchscu.cn+86 19983137946

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026